

References

1. Wolfe, W. et al., (2023). The Challenge of Applications of Probiotics in Gastrointestinal Diseases. *Advanced Gut & Microbiome Research*; Article ID 1984200. <https://doi.org/10.1155/2023/1984200>.
2. Yanfei, Z. et al., (2023). Probiotics fortify intestinal barrier function: a systematic review and meta-analysis of randomized trials. *Front Immunol*; 14: 1143548. doi: [10.3389/fimmu.2023.1143548](https://doi.org/10.3389/fimmu.2023.1143548).
3. Dale, H. F. et al., (2019). Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review. *Nutrients*; 11(9): 2048. doi:[10.3390/nu11092048](https://doi.org/10.3390/nu11092048).
4. Terciolo, C. et al., (2019). Beneficial effects of *Saccharomyces boulardii* CNCM I-745 on clinical disorders associated with intestinal barrier disruption. *Clin Exp Gastroenterol*;12, 67–82. doi: [10.2147/CEG.S181590](https://doi.org/10.2147/CEG.S181590).
5. Vasant, D.H. et al., (2021). British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. *Gut*; 70:1214–1240. doi:[10.1136/gutjnl-2021-324598](https://doi.org/10.1136/gutjnl-2021-324598).
6. Rotheram, S. et al., (2021). How are inequalities generated in the management and consequences of gastrointestinal infections in the UK? An ethnographic study. *Soc Sci Med*; 282:114131. doi: [10.1016/j.socscimed.2021.114131](https://doi.org/10.1016/j.socscimed.2021.114131).
7. NICE (2023). Diarrhoea - antibiotic associated:How common is it?. Online [visited on 12/09/2023]. <https://cks.nice.org.uk/topics/diarrhoea-antibiotic-associated/background-information/prevalence/>.
8. NICE (2023). Constipation:How common is it?. Online [visited on 12/09/2023]. <https://cks.nice.org.uk/topics/constipation/background-information/prevalence/>.
9. Allen, P. et al., (2022). Pediatric Functional Constipation. *StatPearls* [Internet].Bookshelf ID: NBK537037; PMID: [30725722](https://pubmed.ncbi.nlm.nih.gov/30725722/).
10. McFarland, LV. et al., (2018). Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. *Front Med (Lausanne)*; 5:124. doi: [10.3389/fmed.2018.00124](https://doi.org/10.3389/fmed.2018.00124).
11. Willson, Z. et al., (2019). A cross sectional survey to assess healthcare professionals' attitudes to and understanding of probiotics. *Clinical Nutrition ESPEN*; 34:104-109. doi:<https://doi.org/10.1016/j.clnesp.2019.08.004>.
12. Li, B. et al., (2020). Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. *Frontiers in pharmacology*, 11:332. doi:[10.3389/fphar.2020.00332](https://doi.org/10.3389/fphar.2020.00332).
13. Goodman, C. et al., (2021). Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis. *BMJ Open*;11(8): e043054. doi: [10.1136/bmjopen-2020-043054](https://doi.org/10.1136/bmjopen-2020-043054).
14. Guo, Q. et al (2019). Probiotics for the prevention of pediatric antibiotic-associated diarrhea. *Cochrane Database Syst Rev*. 2019 Apr 30;4(4):CD004827. doi: [10.1002/14651858.CD004827](https://doi.org/10.1002/14651858.CD004827).
15. Van Der Schoot, A. et al., (2022). Probiotics and synbiotics in chronic constipation in adults: a systematic review and meta-analysis of randomized controlled trials. *Clinical Nutrition*; 41(12): 2759-2777. Doi: [10.1016/j.clnu.2022.10.015](https://doi.org/10.1016/j.clnu.2022.10.015).
16. Dimidi, E. et al., (2014). The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. *Am J Clin Nutr*; 100(4):1075-84. doi: [10.3945/ajcn.114.089151](https://doi.org/10.3945/ajcn.114.089151).
17. Blaabjerg, S. et al., (2017). Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients-A Systematic Review and Meta-Analysis. *Antibiotics (Basel)*; 6(4):21. doi:[10.3390/antibiotics6040021](https://doi.org/10.3390/antibiotics6040021).

18. AEPbio (2023). Clinical Guide to Probiotic Products Available in USA. Online [visited on 12/09/2023].
http://usprobioticguide.com/PBCAdultHealth.html?utm_source=adult_ind&utm_medium=civ&utm_campaign=USA_CHART.
19. Guarino, A. et al., (2008). ESPGHAN/ESPID Evidence-Based Guidelines for the Management of Acute Gastroenteritis in Children in Europe Expert Working Group. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: executive summary. *J Pediatr Gastroenterol Nutr*; 46(5), 619-21. doi: [10.1097/MPG.0b013e31816e219e](https://doi.org/10.1097/MPG.0b013e31816e219e).
20. Szajewska, H. et al., (2020). Systematic review with meta-analysis: *Saccharomyces boulardii* for treating acute gastroenteritis in children—a 2020 update. *Alimentary Pharmacology & Therapeutics*. doi:[10.1111/apt.15659](https://doi.org/10.1111/apt.15659).
21. Feizizadeh, S. et al., (2014). Efficacy and Safety of *Saccharomyces boulardii* for Acute Diarrhea. *Pediatrics*. 134(1), e176–e191.
22. Czerucka, D. et al., (2019). Diversity of *Saccharomyces boulardii* CNCM I-745 mechanisms of action against intestinal infections. *World J Gastroenterol*; 25(18), 2188–2203.
23. Buccigrossi, V. et al., (2014). Chloride Secretion Induced by Rotavirus Is Oxidative Stress-Dependent and Inhibited by *Saccharomyces boulardii* in Human Enterocytes; *PLoS One*. 9(6), e99830.
24. Htwe, K. et al., (2008). Effect of *Saccharomyces boulardii* in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. *Am J Trop Med Hyg*; 78(2), 214-6.
25. Shan, L. S. et al., (2013). Prevention and treatment of diarrhoea with *Saccharomyces boulardii* in children with acute lower respiratory tract infections. *Beneficial Microbes*; 4(4), 329–334.
26. Surawicz, C. M. et al., (2000). The search for a better treatment for recurrent *Clostridium difficile* disease: use of high-dose vancomycin combined with *Saccharomyces boulardii*. *Clin Infect Dis*; 31(4), 1012-7.
27. Wombwell, E. et al., (2020). The Effect of *Saccharomyces boulardii* Primary Prevention on Risk of Hospital-onset *Clostridioides difficile* Infection in Hospitalized Patients Administered Antibiotics Frequently Associated With *C. difficile* Infection. *Clinical Infectious Diseases*.
<https://doi.org/10.1093/cid/ciaa808>.
28. McFarland, LV. et al., (2021). Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. *EClinicalMedicine*; 18(41):101154. doi: 10.1016/j.eclinm.2021.101154.
29. Eskesen, D. et al., (2015). Effect of the probiotic strain *Bifidobacterium animalis* subsp. *lactis*, BB-12[®], on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial. *British Journal of Nutrition (Human and Clinical Nutrition)*.
<http://dx.doi.org/10.1017/S0007114515003347>.
30. McFarland, LV. et al., (2020). Efficacy of Single-Strain Probiotics Versus Multi-Strain Mixtures: Systematic Review of Strain and Disease Specificity. *Digestive Diseases and Sciences*; 66: 694–704. <https://doi.org/10.1007/s10620-020-06244-z>.
31. Pozzoni, P. et al., (2012). *Saccharomyces boulardii* for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. *Am J Gastroenterol*; 107(6), 922-31.

32. Black, CJ., Ford, AC. (2021). Best management of irritable bowel syndrome. *Frontline Gastroenterology*, 12:303-315.
33. Study Supports Banning Probiotics From the ICU - Medscape - Nov 22, 2022.
34. Rolfe V. et al., (2006). Probiotics for maintenance of remission in Crohn's disease. *Cochrane Database Systematic Rev* John Wiley Sons Ltd. [doi: 10.1002/14651858.CD004826.pub2](https://doi.org/10.1002/14651858.CD004826.pub2).
35. Iheozor-Ejiofor Z, Kaur L, Gordon M, Baines PA, Sinopoulou V, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. *Cochrane Database Systematic Rev* NLM (Medline) (2020) 3:CD007443. [doi: 10.1002/14651858.CD007443.pub3](https://doi.org/10.1002/14651858.CD007443.pub3).
36. Kaur L, Gordon M, Baines PA, Iheozor-Ejiofor Z, Sinopoulou V, Akobeng AK. Probiotics for induction of remission in ulcerative colitis. *Cochrane Database Systematic Rev* NLM (Medline) (2020) 3:CD005573. [doi: 10.1002/14651858.CD005573.pub3](https://doi.org/10.1002/14651858.CD005573.pub3).
37. Rodriguez-Arrastia, M. et al., (2021). Probiotic Supplements on Oncology Patients' Treatment-Related Side Effects: A Systematic Review of Randomized Controlled Trials. *Int J Environ Res Public Health*. 2021 Apr 17;18(8):4265. [doi: 10.3390/ijerph18084265](https://doi.org/10.3390/ijerph18084265).
38. Probiotics - Medscape - Mar 15, 2010.
39. Pineda, M. et al., (2011). A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. *Med Sci Monit*. 2011 Jun;17(6):CR347-54. [doi: 10.12659/msm.881808](https://doi.org/10.12659/msm.881808).
40. Alsuwaylihi AS. et al., (2023). The safety and efficacy of probiotic supplementation for critically ill adult patients: a systematic review and meta-analysis. *Nutr Rev*; 81(3):322-332. [doi: 10.1093/nutrit/nuac059](https://doi.org/10.1093/nutrit/nuac059).